• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine

tetano

Editor, Senior Moderator
Sci Rep


. 2024 Feb 20;14(1):4204.
doi: 10.1038/s41598-024-54421-1. Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine

Chimuka Handabile[SUP] 1 2 [/SUP], Marumi Ohno[SUP] 1 2 3 [/SUP], Toshiki Sekiya[SUP] 1 2 4 5 [/SUP], Naoki Nomura[SUP] 1 2 6 [/SUP], Tomomi Kawakita[SUP] 1 7 [/SUP], Mamiko Kawahara[SUP] 2 [/SUP], Masafumi Endo[SUP] 8 [/SUP], Tomohiro Nishimura[SUP] 8 [/SUP], Minako Okumura[SUP] 8 [/SUP], Shinsuke Toba[SUP] 9 10 [/SUP], Michihito Sasaki[SUP] 1 10 [/SUP], Yasuko Orba[SUP] 1 10 [/SUP], Brendon Y Chua[SUP] 4 5 [/SUP], Louise C Rowntree[SUP] 5 [/SUP], Thi H O Nguyen[SUP] 5 [/SUP], Masashi Shingai[SUP] 1 2 4 7 [/SUP], Akihiko Sato[SUP] 1 9 10 [/SUP], Hirofumi Sawa[SUP] 1 3 4 10 [/SUP], Kazumasa Ogasawara[SUP] 2 [/SUP], Katherine Kedzierska[SUP] 1 4 5 [/SUP], Hiroshi Kida[SUP] 11 12 13 14 [/SUP]



Affiliations
Abstract

Due to the synchronous circulation of seasonal influenza viruses and severe acute respiratory coronavirus 2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19), there is need for routine vaccination for both COVID-19 and influenza to reduce disease severity. Here, we prepared individual WPVs composed of formalin-inactivated SARS-CoV-2 WK 521 (Ancestral strain; Co WPV) or influenza virus [A/California/07/2009 (X-179A) (H1N1) pdm; Flu WPV] to produce a two-in-one Co/Flu WPV. Serum analysis from vaccinated mice revealed that a single dose of Co/Flu WPV induced antigen-specific neutralizing antibodies against both viruses, similar to those induced by either type of WPV alone. Following infection with either virus, mice vaccinated with Co/Flu WPV showed no weight loss, reduced pneumonia and viral titers in the lung, and lower gene expression of proinflammatory cytokines, as observed with individual WPV-vaccinated. Furthermore, a pentavalent vaccine (Co/qFlu WPV) comprising of Co WPV and quadrivalent influenza vaccine (qFlu WPV) was immunogenic and protected animals from severe COVID-19. These results suggest that a single dose of the two-in-one WPV provides efficient protection against SARS-CoV-2 and influenza virus infections with no evidence of vaccine interference in mice. We propose that concomitant vaccination with the two-in-one WPV can be useful for controlling both diseases.


 
Back
Top Bottom